Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
6.55
-0.04 (-0.61%)
Aug 26, 2026, 12:12 PM EDT - Market open
Prelude Therapeutics Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Prelude Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.00. The average 1-year stock price forecast is 22.14% higher than the current stock price, while the lowest is $6.00 (-8.40%) and the highest is $10 (+52.67%).
Price Target: $8.00 (+22.14%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Prelude Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +22.14% | Jul 29, 2026 |
| D. Boral Capital | D. Boral Capital | Buy Initiates $9 | Buy | Initiates | $9 | +37.40% | May 4, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $3 → $6 | Buy | Maintains | $3 → $6 | -8.40% | Mar 11, 2026 |
Financial Forecast
Revenue This Year
4.58M
from 12.14M
Decreased by -62.27%
Revenue Next Year
100.00M
from 4.58M
Increased by 2,083.41%
EPS This Year
-0.54
from -1.29
EPS Next Year
-0.75
from -0.54
EPS and Forward PE are based on non-GAAP adjusted numbers.